Allarity Therapeutics, Inc. SEC filings document the company’s clinical-stage oncology business, capital structure, governance, and material-event disclosures. The filings identify Allarity’s Nasdaq-listed common stock and emerging growth company status, and include 8-K reports covering Regulation FD presentations, scientific and clinical updates for stenoparib and the DRP® companion diagnostic, intellectual-property developments, operating and financial results, and promissory-note financing.
Proxy materials describe annual meeting matters and stockholder voting procedures, while material definitive agreement filings and other current reports provide formal disclosure on financing arrangements, corporate progress, and regulatory or clinical communications tied to Allarity’s precision oncology programs.
Allarity Therapeutics, Inc. President and Chief Development Officer Jeremy R. Graff reported settling 48,147 restricted stock units into common stock on January 22, 2026, and 39,494 units on September 30, 2026. On those dates, the issuer withheld 17,814 and 14,613 common shares, respectively, to satisfy tax withholding obligations; the applicable vesting-date fair market values were $1.18 and $0.97 per share, respectively. After the January 22, 2026 vesting and withholding and January 28, 2026 grant, stated balances were 55,214 common shares and 308,616 unvested restricted stock units.
Allarity Therapeutics, Inc. reported advances in its Drug Response Predictor (DRP®) technology, patent portfolio and in-house laboratory capabilities, which the company says support stenoparib’s clinical development and potential external partnerships. The stenoparib DRP uses a 414-gene expression signature.
An exploratory analysis of a prior Phase 2 advanced ovarian cancer cohort treated with stenoparib twice daily found higher pretreatment DRP scores associated with longer overall survival. Allarity said recent patent awards and CLIA certification of its in-house lab allow it to extend the test’s use as a companion diagnostic and retain sole control of the clinical test. A separate Phase 2 trial combining stenoparib with temozolomide for relapsed small cell lung cancer began enrolling in early 2026 and is enrolling at multiple U.S. Department of Veterans Affairs sites.
Allarity Therapeutics, Inc. (ALLR) expanded its in-house medical laboratory to include proteomics and cell line research, alongside existing transcriptomics research and CLIA clinical testing. The nCounter Human Tumor Signaling Protein Panel can now be used for proteomics research and measures approximately 300 protein targets. Allarity says the added capabilities will support further mechanism-of-action research on stenoparib and broaden the research projects and laboratory services it can offer external partners.
The company says the expansion will not affect its current cash runway and may generate significant cost efficiencies by allowing more research to be conducted in-house. A separate Phase 2 trial of stenoparib plus temozolomide for relapsed small cell lung cancer began enrolling in early 2026 and is enrolling at multiple U.S. Department of Veterans Affairs sites.
Allarity Therapeutics, Inc. (ALLR) reported that the Japan Patent Office has granted Japanese Patent No. 7917283, a key patent covering its proprietary stenoparib-specific Drug Response Predictor (DRP®) companion diagnostic, providing patent protection in Japan into 2039.
The patent covers DRP methods for predicting clinical benefit from stenoparib based on tumor gene-expression profiles and for selecting patients most likely to benefit from stenoparib treatment. Allarity already holds stenoparib DRP® patents in the United States, with protection into April 2042, as well as in certain European jurisdictions and Australia, and is advancing stenoparib through Phase 2 trials in ovarian and small cell lung cancer.
Allarity Therapeutics, Inc. (ALLR) disclosed that Allarity Acquisition Corp., a newly formed special purpose acquisition company sponsored by ALLR Sponsor LLC, has publicly filed a Form S-1 for a proposed Nasdaq-listed IPO of its units. The base offering size is expected to be $100 million, increasing to $115 million if the underwriters’ over-allotment option is exercised in full.
ALLR Sponsor LLC, a wholly owned subsidiary of Allarity, is expected to own about 25.0% of Allarity Acquisition Corp.’s issued and outstanding ordinary shares after the offering, as described in the S-1. The SPAC may pursue a business combination in any industry or region, and has applied to list its units on Nasdaq under the symbol ALLNU. Allarity stated that this SPAC initiative does not change its expectation that existing working capital can fund operations into the summer of 2028.
Allarity Therapeutics, Inc. reported second-quarter 2026 results and development progress for stenoparib, its dual PARP/tankyrase inhibitor for cancer. For the quarter ended June 30, 2026, the company generated no revenue and recorded a net loss of $3.4 million, compared with $2.3 million a year earlier, as other income swung to a net expense. Total operating expenses fell to $2.7 million from $4.1 million, reflecting lower research and development and general and administrative costs.
At June 30, 2026, Allarity held $17.0 million in cash and $10.0 million in restricted cash, with total assets of $32.1 million. Total liabilities rose to $28.6 million, driven largely by a new short-term promissory note of $20.9 million, reducing stockholders’ equity to $3.5 million. Operationally, the company completed a Phase 3-ready stenoparib manufacturing campaign, obtained CLIA certification for its in-house DRP companion diagnostic laboratory, and highlighted a newly granted U.S. patent extending stenoparib DRP exclusivity into 2042.
Allarity Therapeutics, Inc., a clinical-stage oncology company, reported continued operating losses but a strengthened cash position for the quarter and six months ended June 30, 2026. Total assets were $32.1 million, up from $18.3 million at year-end, driven mainly by cash and restricted cash of $26.9 million.
The company recorded a six‑month net loss of $6.2 million (basic and diluted loss per share $0.39) on minimal revenue of $0.025 million from DRP testing services. Operating expenses declined year over year, with research and development at $2.6 million and general and administrative at $2.7 million for the six‑month period, reflecting lower clinical and legal costs.
To fund operations, Allarity completed a $20.0 million dual‑note financing with Streeterville Capital and established a $6.0 million equity line of credit with Tumim Stone Capital. Total liabilities increased to $28.6 million, and stockholders’ equity fell to $3.5 million. Management states existing cash and restricted cash are expected to fund operations for at least twelve months from the financial statement issuance date.
Allarity Therapeutics, Inc. reported results from its annual stockholder meeting and announced a newly granted U.S. patent. Stockholders elected Jesper Hoiland as director and ratified Wolf & Company, P.C. as auditor. They also approved an increase in shares available under the 2021 Equity Incentive Plan and an advisory vote on executive compensation.
Holders approved issuing common stock under a January 2026 Common Stock Purchase Agreement with Tumim Stone Capital LLC above the exchange cap, while an amendment to limit certain officer liability did not pass. Separately, the USPTO granted a key U.S. patent for Allarity’s stenoparib-specific DRP companion diagnostic, with a term extending into April 2042, supporting the company’s personalized oncology strategy.
Allarity Therapeutics, Inc. filed an 8-K to share a press release about presenting a Trial-in-Progress poster on its ongoing Phase 2 trial of stenoparib in advanced platinum-resistant or platinum-ineligible ovarian cancer at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen.
The poster explains the scientific background, study design, and clinical rationale, but does not include new clinical data. Allarity highlights prior Phase 2 experience showing durable clinical benefit in heavily pretreated ovarian cancer patients and its DRP® companion diagnostic strategy to select patients most likely to benefit from stenoparib.
Allarity Therapeutics, Inc. entered into an amended and restated Management Services Agreement with Ljungaskog Consulting AB, the firm of CEO Thomas H. Jensen, effective June 1, 2026. The agreement fully replaces the prior 2024 management services arrangement.
The consultant’s 2026 base compensation will be paid 80% in Swedish Krona and 20% in U.S. dollars, equal to SEK 6,000,000 and US$163,043. The prior one-time US$100,000 signing bonus is removed. Annual bonus metrics are to be set each year, with any bonus capped at 60% of fees paid and, if earned, payable by March 15 following year-end.
For a termination by the company for convenience, the notice period increases from 15 to 30 days and the consultant becomes eligible for a termination payment equal to 12 months of the monthly fee, in addition to accrued amounts, subject to conditions such as a release and cooperation. Upon a termination by the consultant for Good Reason, severance increases from nine months to 12 months of the monthly fee on similar conditions. The agreement also adds provisions addressing Sections 409A and 280G of the U.S. Internal Revenue Code when applicable.